Koenig Sheldon L. 4
4 · Esperion Therapeutics, Inc. · Filed Sep 18, 2025
Insider Transaction Report
Form 4
Koenig Sheldon L.
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2025-09-17$2.79/sh−28,427$79,254→ 1,518,831 total
Footnotes (2)
- [F1]Shares were sold to satisfy tax obligation on vested shares of restricted stock units.
- [F2]Includes 5,770 shares recently acquired in Esperion's Employee Stock Purchase Plan.